氨己烯酸口服溶液用散对眼睛有什么影响

What effect does it have on the eyes?

Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that may lead to disability. In some cases, vigabatrin can also damage the central retina and may reduce vision.

The onset of vigabatrin-induced vision loss is unpredictable and can occur within weeks or sooner of starting treatment, or at any time after starting treatment, even months or years later.

Symptoms of vision loss caused by vigabatrin are unlikely to be recognized by patients or caregivers until vision loss is severe. Mild vision loss, although often unrecognized by patients or caregivers, can still adversely affect function.

The risk of vision loss increases with dose and cumulative exposure, but there is no known dose or exposure without risk of vision loss.

Vision evaluation is recommended at baseline (no later than 4 weeks after starting vigabatrin), at least every 3 months during treatment, and approximately 3 to 6 months after stopping treatment.

Once detected, vigabatrin-induced vision loss is irreversible. It is expected that some patients will experience severe vision loss even with frequent monitoring.

If vision loss is documented, consider balancing the benefits and risks.

The risk of new or worsening vision loss continues as long as vigabatrin is used. Vision loss may worsen despite discontinuation of vigabatrin.

Due to the risk of vision loss, vigabatrin should be discontinued earlier if within 3 months of starting treatment in patients with refractory complex partial seizures and within 2-4 weeks of starting treatment in patients with infantile spasms if treatment failure is evident. Patients' response to and ongoing need for vigabatrin should be periodically reassessed.

Vigabatrin should not be used in patients with or at high risk for other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks.

Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects (such as retinopathy or glaucoma) unless the benefits clearly outweigh the risks.

Use the lowest dose and shortest exposure to vigabatrin consistent with clinical goals.

Due to the risk of permanent vision loss, vigabatrin is only available through a restricted program under the Risk Evaluation and Mitigation Strategy (REMS), called the vigabatrin REMS program.

For more information about the effects of vigabatrin oral solution powder on the eyes, you can read the drug instructions. It is recommended that patients take medication under the guidance of a doctor and treat symptoms accordingly.

Recommended related articles: